醒脑静注射液联合依达拉奉治疗老年脑出血急性期患者的疗效及预后分析

Analysis on the Clinical Efficacy and Prognosis of Xingnaojing Injection Combined with Edaravone in the Treatment of Elderly Patients with Acute Cerebral Hemorrhage

目的探讨醒脑静注射液联合依达拉奉治疗老年脑出血急性期患者的临床疗效及预后情况。方法选择2016年8月至2017年12月我院收治的老年脑出血患者80例,随机分为对照组和干预组各40例,对照组采用依达拉奉注射液治疗,干预组在对照组基础上采用醒脑静注射液治疗,两组患者均治疗2周。观察两组患者的临床疗效,并随访6个月,观察两组患者治疗前后的ADL、NIHSS评分。结果干预组的治疗总有效率为87.50%,明显高于对照组的67.50%(P<0.05)。治疗前,两组患者的ADL、NIHSS评分比较无统计学差异(P>0.05);治疗后,两组患者的ADL评分高于治疗前,NIHSS评分低于治疗前,且干预组的ADL、NIHSS评分均明显优于对照组(P均<0.05)。结论采用醒脑静注射液联合依达拉奉治疗脑出血急性期患者的临床疗效显著,可有效改善其生活能力和神经功能缺损程度,患者预后情况良好,值得临床推广。

Objective To explore the clinical efficacy and prognosis of Xingnaojing injection combined with edaravone in the treatment of patients with acute cerebral hemorrhage.Methods 80 elderly patients with cerebral hemorrhage admitted to our hospital from August 2016 to December 2017 were selected and randomly divided into control group and intervention group,with 40 cases in each group.The control group was treated with edaravone injection,and the intervention group was treated with Xingnaojing injection on the basis of the control group.Both groups were treated for 2 weeks.The clinical efficacy of the two groups was observed.Followed up for 6 months,the ADL and NIHSS scores of the two groups were observed before and after treatment.Results The total effective rate of treatment in the intervention group was 87.50%,significantly higher than 67.50%in the control group(P<0.05).Before treatment,no statistical difference was found in the ADL and NIHSS scores between the two groups(P>0.05).After treatment,the ADL scores of the two groups were higher than those before treatment,and the NIHSS scores were lower than those before treatment(all P<0.05);The ADL and NIHSS scores of the intervention group were significantly better than those of the control group(P<0.05).Conclusions Xingnaojing injection combined with edaravone in the treatment of patients with acute cerebral hemorrhage has significant clinical efficacy,and can effectively improve patients’quality of life and neurological impairment with good prognosis,which is worthy of clinical promotion.